| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $60,699,527 ) (Continued on the next page) |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA276156 | Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies | 000 | 3 | NIH | 11/22/2024 | $362,793 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA214608 | The molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase | 000 | 9 | NIH | 3/20/2025 | $363,568 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01HL158269 | Tracing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms | 000 | 5 | NIH | 1/17/2025 | $442,500 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01AG075837 | Contribution of a novel OPN-producing CD11c+ microglial subset to AD | 000 | 2 | NIH | 12/6/2024 | $455,377 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA283154 | Targeting mitochondrial vulnerabilities to drive intrinsic melanoma immunogenicity | 000 | 2 | NIH | 3/4/2025 | $128,798 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA286805 | Dissecting the Role of Germline Genetics in RAS-Driven Cancers | 000 | 2 | NIH | 1/13/2025 | $163,728 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA276268 | Mechanisms of response and resistance to KRAS inhibition in pancreatic cancer | 000 | 3 | NIH | 12/16/2024 | $505,595 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA283395 | Mechanisms of Toxicity Induced by EWS/FLI1 Overdose in Ewing Sarcoma | 000 | 3 | NIH | 4/16/2025 | $642,235 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21CA296230 | Targeting the CDK4/6 pathway in MiT/TFE-translocation renal cell carcinoma | 000 | 1 | NIH | 1/30/2025 | $267,298 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA265928 | A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies | 000 | 4 | NIH | 1/28/2025 | $606,827 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA262188 | Development of a generalizable chemo-proteomics screening platform for small molecule degraders applied to HDACs | 000 | 4 | NIH | 4/11/2025 | $410,300 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01HL157174 | Systematic identification of minor histocompatibility antigens to address GVHD | 000 | 4 | NIH | 3/25/2025 | $691,415 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA279891 | Epigenetic regulators define a dynamic chromatin landscape in NUP98-rearranged leukemia | 000 | 2 | NIH | 1/27/2025 | $215,179 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA262462 | Synthetic lethalities to cell cycle disruption in glioma | 000 | 4 | NIH | 5/8/2025 | $673,491 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA252169 | Characterizing the XRN1 exoribonuclease as a therapeutic target in non-small cell lung cancer | 000 | 5 | NIH | 5/14/2025 | $208,829 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA271605 | Cell lineage as an indicator of immune response in neuroblastoma | 000 | 4 | NIH | 4/21/2025 | $364,840 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA300092 | Mapping the epigenetic dynamics of prostate cancer progression: integrating liquid biopsies and single-cell epigenomics for early detection of lineage plasticity and clinical decision-making | 000 | 1 | NIH | 2/27/2025 | $627,474 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA279221 | Dissecting Integrated Cellular Programs Promoting Platinum Resistance and Progression in Bladder Cancer | 000 | 2 | NIH | 3/4/2025 | $652,606 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01DK078081 | Metabolic crosstalks in regulation of beta-cell stress response and adaptation | 000 | 13 | NIH | 3/3/2025 | $443,718 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | UG1CA233180 | NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care | 000 | 6 | NIH | 3/5/2025 | $664,023 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA253731 | Targeting Oncogenic Drivers in Cancer | 000 | 6 | NIH | 2/14/2025 | $97,605 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA283279 | Molecular Dynamics of Glioma Formation and DNA Damage Response by Mutant IDH1 | 000 | 2 | NIH | 3/13/2025 | $299,403 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA248727 | Investigating Transcriptional Elongation and Nuclear RNA Surveillance in Melanoma | 000 | 6 | NIH | 3/7/2025 | $195,902 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA155010 | Personal tumor neoantigens for immunity against chronic lymphocytic leukemia | 000 | 14 | NIH | 2/14/2025 | $683,283 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA284279 | Evaluating METTL1-mediated m7G tRNA methylation as a novel dependency in alveolar rhadomyosarcoma | 000 | 3 | NIH | 5/2/2025 | $99,576 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA245819 | Investigating Immune Responses to Neoantigen Cancer Vaccines using In Vivo Functionalized Lineage | 000 | 6 | NIH | 12/10/2024 | $105,840 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA251470 | Yoga for Chemotherapy-induced Peripheral Neuropathy Treatment (YCT) Trial | 002 | 6 | NIH | 4/7/2025 | $634,897 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01AI158488 | CDK4/6 inhibition during CD8 T cell priming potentiates memory formation in mice and humans | 000 | 5 | NIH | 3/28/2025 | $445,000 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA269574 | Promoting Resilience in Early Survivorship among Adolescents and Young Adults with Cancer | 000 | 4 | NIH | 4/10/2025 | $784,932 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA259623 | Elucidating the impact of DNA hypomethylation on genome organization and anti-tumor transcriptional programs | 000 | 6 | NIH | 3/26/2025 | $195,134 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA259365 | Structure-activity relationships governing mammalian SWI/SNF chromatin remodeling activity as a function of chromatin state | 000 | 5 | NIH | 4/21/2025 | $621,332 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA258924 | Genetic Predisposition to Chronic Lymphocytic Leukemia (CLL) | 000 | 5 | NIH | 4/21/2025 | $532,020 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA251555 | Elucidation of the genetic mechanisms driving prostate tumorigenesis through integrative computational and functional approaches | 000 | 5 | NIH | 3/10/2025 | $607,593 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA279391 | Merkel cell polyomavirus HLA class I epitopes for generating therapeutic T cell-based cancer immunotherapy | 000 | 2 | NIH | 2/13/2025 | $633,159 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA258688 | Optimizing Therapeutic STING Agonism in Triple Negative Breast Cancer | 000 | 5 | NIH | 3/13/2025 | $366,458 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32CA284750 | Investigating IGF2BP1 as a novel Therapeutic Target for Ewing Sarcoma | 000 | 2 | NIH | 3/12/2025 | $74,284 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA248393 | Development of microRNA (miR)-based cell-targeted polymeric nanoparticles for myeloma therapy | 000 | 5 | NIH | 3/12/2025 | $495,790 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U10CA180794 | ECOG-ACRIN Network Group Statistics and Data Management Center | 000 | 11 | NIH | 2/28/2025 | $4,683,890 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA284254 | Defining Therapeutically Targetable Regulators of Tumor-Intrinsic Immune Suppression in Glioblastoma | 000 | 3 | NIH | 2/13/2025 | $99,216 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21CA288234 | Investigating Interactions Between Radiation and Antibody-Drug Conjugates in Bladder Cancer | 000 | 2 | NIH | 2/13/2025 | $222,106 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA269285 | Cyclin C-CDK8/19 kinases in development and in cancer | 000 | 4 | NIH | 3/4/2025 | $473,373 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01CA286537 | Mechanism and functional consequences of dietary lipids in lineage specification and tumor growth in oncohistone gliomas | 000 | 2 | NIH | 3/4/2025 | $632,213 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA097098 | Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer | 001 | 21 | NIH | 3/7/2025 | $416,042 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R00CA266921 | SESORRS endoscopy for the staging and evaluation of colorectal cancer | 000 | 4 | NIH | 12/23/2024 | $170,893 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01AI179839 | High-throughput single-cell RNA sequencing of bacteria to uncover cell states involved in pathogenesis | 000 | 2 | NIH | 5/6/2025 | $813,272 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01HL171973 | Molecular mechanisms of splicing dependency in cohesin-mutant myelodysplasia | 000 | 2 | NIH | 11/18/2024 | $400,500 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R61CA278449 | New Chemical Tools for Covalent Drug Discovery | 000 | 2 | NIH | 1/9/2025 | $224,681 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA221874 | Comprehensive minimal residual disease tracking in cancer | 000 | 5 | NIH | 11/4/2024 | $399,996 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R37CA269990 | Mechanisms by which LSD1 Promotes Neuroendocrine Differentiation and Small Cell Lung Cancer | 000 | 3 | NIH | 11/6/2024 | $420,355 |
|
